day 30 suvmax to predict progression in patients with lbcl achieving pr after car-t therapy
Published 2 years ago • 293 plays • Length 2:39Download video MP4
Download video MP3
Similar videos
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
4:16
the challenges with car t-cell therapy for t-all and the progress made to overcome these challenges
-
1:15
cd30, a promising target for car-t therapy in hodgkin lymphoma
-
1:07
optimizing car-t therapy: regulating car t-cells in vivo
-
0:59
identifying molecular markers for the prediction of icaht in patients receiving car t-cell therapy
-
6:24
results of the transcend study of car t cell product jcar017 in patients with r/r aggressive b-nhl
-
4:17
using serum proteomics & the ht10 score to distinguish between infections & crs after car-t therapy
-
4:06
cd30-directed car-ts co-expressing ccr4 in r/r hl and cd30 ctcl
-
1:42
infusion of cd30 car t-cells following auhct in patients with lymphoma
-
3:01
phase 1 trial of car t-cell therapy for lymphoma
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
4:10
car t-cell therapy for all
-
1:01
the potentially curative role of car-t therapy in myeloma
-
2:25
the impact of tafasitamab on the efficacy and safety of cd19 car-t therapy in preclinical models
-
3:03
the impact of salvage and bridging therapy on car t-cell therapy outcomes in b-all: an itt analysis
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
4:17
preparing for the commercialization of car-t products